等待開盤 09-20 09:30:00 美东时间
0.000
0.00%
HC Wainwright & Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $90 price target.
今天 18:37
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Cytokinetic...
今天 18:27
Bank of America Securities analyst Jason Zemansky has maintained their neutral ...
今天 16:45
HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant sales potential for Enliven's therapies.
09-10 02:05
Cantor Fitzgerald analyst Charles Duncan reiterates Cytokinetics (NASDAQ:CYTK) with a Overweight.
09-10 01:00
Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that data from the Phase 1 study of CK-4021586 (CK-586) were presented in a poster session at the American College of Clinical Pharmacology (ACCP) Annual Meeting
09-09 19:33
Cytokinetics, Incorporated (NASDAQ:CYTK) today announced two presentations at the 2024 American College of Clinical Pharmacology (ACCP) Annual Meeting in Bethesda, MD from September 8, 2024 – September 10, 2024.
09-06 04:18
Analyst Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Cytoki...
09-03 13:15
Cytokinetics Inc : Jefferies Raises Target Price to $92 From $85
08-22 21:35
BioMarin Pharmaceutical (NASDAQ:BMRN) unveiled a major leadership shakeup on Wednesday, appointing a new business chief and a new head of Research & Development. Accordingly, Greg Friberg will join as...
08-21 21:31